Puspa Raj Pandey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Puspa Raj Pandey has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Bishwanath Chatterjee
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
11 shared publications - Frederic G. Barr
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892
11 shared publications - Hana Kim
National Cancer Institute 1 Laboratory of Pathology, Center for Cancer Research Bethesda, Maryland
11 shared publications - Pawan Kumar Raut
National Cancer Institute 1 Laboratory of Pathology, Center for Cancer Research Bethesda, Maryland
11 shared publications - Wenyue Sun
National Cancer Institute 13 Laboratory of Pathology, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
11 shared publications - Reyaz Ur Rasool
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland
10 shared publications
Latest Publications
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Supplementary Table 1 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Supplementary Table 1 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Effect of FGF8 on FGFR4 expression in human myoblast cell lines
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Effect of FGF8 on FGFR4 expression in human myoblast cell lines
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Supplementary Table 2 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Supplementary Table 2 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Effect of FGFR inhibitors on colony growth of FP-RMS cells
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Effect of FGFR inhibitors on colony growth of FP-RMS cells
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Gene reporter assay investigating the regulatory effect of the LTR
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Gene reporter assay investigating the regulatory effect of the LTR
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Effect of high FGF8 expression on P3F-induced expression of FGFR4
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Effect of high FGF8 expression on P3F-induced expression of FGFR4
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Expression of FGFs and FGFRs in RMS tumors
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
Expression of FGFs and FGFRs in RMS tumors
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Data from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
We previously used a myoblast model of fusion-positive rhabdomyosarcoma (FP-RMS) to show that FGF8, a PAX3–FOXO1 (P3F) transcriptional target, is required for P3F-driven tumorigenicity and, when aberrantly expressed, can maintain tumorigenicity in P3F-independent recurrent tumors. We report in this study that FGF8, FGFR1, and FGFR4 are often highly expressed in FP-RMS tumors. High FGF8 expression in FP-RMS cells is associated with high sensitivity to an FGFR4 inhibitor and a pan-FGFR inhibitor. Although downregulating FGF8 resulted in loss of sensitivity to these inhibitors, FGF8 upregulation in myoblasts decreased FGFR4 expression and sensitized the cells to an FGFR1 inhibitor and a pan-FGFR inhibitor. FGF8 downregulation of FGFR4 expression was reverted by inhibitors of FGFR1, MEK, or ERK, thus defining a signaling pathway by which FGF8 mediates this regulatory effect. Finally, high FGF8 expression in P3F-independent recurrent tumors was attributable to a rearrangement of viral long terminal repeat (LTR) sequences into the FGF8 3′ untranslated region, resulting in increased FGF8 mRNA stability. These findings indicate that FGF8 exerts oncogenic effects in FP-RMS via FGFR4 and may exert oncogenic effects in P3F-independent relapses via FGFR1. Our study reveals the functional significance of FGF8 in FP-RMS and provides a rationale for preclinical studies of FGFR inhibitors in FP-RMS.
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
We previously used a myoblast model of fusion-positive rhabdomyosarcoma (FP-RMS) to show that FGF8, a PAX3–FOXO1 (P3F) transcriptional target, is required for P3F-driven tumorigenicity and, when aberrantly expressed, can maintain tumorigenicity in P3F-independent recurrent tumors. We report in this study that FGF8, FGFR1, and FGFR4 are often highly expressed in FP-RMS tumors. High FGF8 expression in FP-RMS cells is associated with high sensitivity to an FGFR4 inhibitor and a pan-FGFR inhibitor. Although downregulating FGF8 resulted in loss of sensitivity to these inhibitors, FGF8 upregulation in myoblasts decreased FGFR4 expression and sensitized the cells to an FGFR1 inhibitor and a pan-FGFR inhibitor. FGF8 downregulation of FGFR4 expression was reverted by inhibitors of FGFR1, MEK, or ERK, thus defining a signaling pathway by which FGF8 mediates this regulatory effect. Finally, high FGF8 expression in P3F-independent recurrent tumors was attributable to a rearrangement of viral long terminal repeat (LTR) sequences into the FGF8 3′ untranslated region, resulting in increased FGF8 mRNA stability. These findings indicate that FGF8 exerts oncogenic effects in FP-RMS via FGFR4 and may exert oncogenic effects in P3F-independent relapses via FGFR1. Our study reveals the functional significance of FGF8 in FP-RMS and provides a rationale for preclinical studies of FGFR inhibitors in FP-RMS.
- Open Access
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
RNA expression in engineered FP-RMS cells and myoblast lines
- 2 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma
RNA expression in engineered FP-RMS cells and myoblast lines
- Open Access
Role of Myc family proteins in transcriptional regulation of growth and oncogenic transformation in fusion-positive rhabdomyosarcoma
Fusion-positive rhabdomyosarcoma (FP-RMS) is driven by a PAX 3::FOXO1 (P3F) or PAX7::FOXO1 fusion gene. After finding that MYCN is required for P3F-induced oncogenic transformation in a human myoblast model of FP-RMS, we further investigated the role of Myc family proteins in FP-RMS. Expression studies revealed that myoblast models and a subset of FP-RMS lines have predominant MYCN or MYC expression whereas other FP-RMS lines have both high MYCN and MYC expression. In myoblast models, MYCN was required for optimal P3F binding to and high-level activation of FGF8 , a P3F target that is necessary and sufficient for oncogenic transformation. MYCN or MYC knockdown suppressed transformation in myoblast and FP-RMS lines with dominant MYCN or MYC expression, respectively. In FP-RMS lines with high MYCN and MYC expression, there was partial loss of transformation when one gene was targeted and complete loss when both genes were targeted. Despite the loss of oncogenic activity in lines with knockdown of a dominant Myc family member, FGF8 expression was not decreased. Transcriptomic analyses revealed that P3F target genes were not affected by MYCN or MYC knockdown, and instead a group of Myc-specific targets was down-regulated. Collectively, these results indicate that MYCN or MYC is functionally dominant in myoblast models and FP-RMS lines with dominant expression of one Myc family protein whereas MYCN and MYC are functionally redundant in FP-RMS cell lines with high expression of both. These Myc family proteins contribute to oncogenic properties by facilitating P3F activation of FGF8 and increasing expression of Myc-specific targets.
Open AccessRole of Myc family proteins in transcriptional regulation of growth and oncogenic transformation in fusion-positive rhabdomyosarcoma
Fusion-positive rhabdomyosarcoma (FP-RMS) is driven by a PAX 3::FOXO1 (P3F) or PAX7::FOXO1 fusion gene. After finding that MYCN is required for P3F-induced oncogenic transformation in a human myoblast model of FP-RMS, we further investigated the role of Myc family proteins in FP-RMS. Expression studies revealed that myoblast models and a subset of FP-RMS lines have predominant MYCN or MYC expression whereas other FP-RMS lines have both high MYCN and MYC expression. In myoblast models, MYCN was required for optimal P3F binding to and high-level activation of FGF8 , a P3F target that is necessary and sufficient for oncogenic transformation. MYCN or MYC knockdown suppressed transformation in myoblast and FP-RMS lines with dominant MYCN or MYC expression, respectively. In FP-RMS lines with high MYCN and MYC expression, there was partial loss of transformation when one gene was targeted and complete loss when both genes were targeted. Despite the loss of oncogenic activity in lines with knockdown of a dominant Myc family member, FGF8 expression was not decreased. Transcriptomic analyses revealed that P3F target genes were not affected by MYCN or MYC knockdown, and instead a group of Myc-specific targets was down-regulated. Collectively, these results indicate that MYCN or MYC is functionally dominant in myoblast models and FP-RMS lines with dominant expression of one Myc family protein whereas MYCN and MYC are functionally redundant in FP-RMS cell lines with high expression of both. These Myc family proteins contribute to oncogenic properties by facilitating P3F activation of FGF8 and increasing expression of Myc-specific targets.